Isomorphic Labs Raises $5 Billion for AI-Designed Drugs
Isomorphic Labs, which started inside DeepMind in 2021, just raised $5 billion. The money is meant to move its AI-designed drugs into human trials, the longest and riskiest stage. The company's valuation hasn't been disclosed.
A $5 billion round, and who's in it
This is a Series C, the name for a large funding round raised before a possible IPO. It's led by Greenoaks and Sequoia Capital. Andreessen Horowitz is joining as a new investor, and existing backers such as GV, Capital G, Thrive Capital, MGX, Temasek and the British government's U.K. Sovereign AI Fund are taking part. The previous round, a $2.1 billion Series B, came in May 2026.
On valuation, the company isn't saying. Bloomberg reported a $50 billion target in early November, but the company hasn't confirmed that number.
Demis Hassabis and the drugmakers
Demis Hassabis ran DeepMind, Google's AI lab, and shared the Nobel Prize in Chemistry with John Jumper for AlphaFold, a program that predicts the shape of proteins. He stepped down from running DeepMind and now chairs Isomorphic Labs. This is the company's first funding round since that move.
Isomorphic Labs doesn't sell software to end customers. It designs drug candidates, then looks for pharmaceutical partners to develop them. The article names Eli Lilly, Novartis and Johnson & Johnson as partners, without giving the amounts or the programs involved.
Why clinical trials make the difference
Finding a molecule on a computer that could treat a disease is a first step. Next, it has to be tested in the lab, then on human volunteers, in several phases. That's where most drug candidates fail, because they aren't effective enough or safe enough.
The company says it has obtained positive preclinical results in oncology, the treatment of cancer, and in immunology. These results come from tests outside human trials. They point to a lead, not a drug.
To understand how investors are positioning themselves on AI right now, read OpenAI scales back its funding round: what it tells us.
What the article doesn't specify
The article doesn't name the drug candidates, the exact diseases targeted, or the timeline and number of trials. It also doesn't say how the $5 billion will be split up, or what the financial terms of the partnerships with the drugmakers are.
Key takeaways
- Isomorphic Labs raises $5 billion in a Series C led by Greenoaks and Sequoia Capital.
- The valuation hasn't been disclosed. Bloomberg mentions $50 billion, a number that hasn't been confirmed.
- The company wants to move its drug candidates into clinical trials.
- No amounts have been made public for the partnerships with Lilly, Novartis and Johnson & Johnson.
Translated with the help of AI from our French article, which is prepared with AI from the sources, then reviewed and approved by Valentin Fouilloud before publication. How we work